Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

3 Months Ended

Mar. 31, 2025

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

13. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2025 and 2024 (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2025			2024
Net loss attributable to Adaptive Biotechnologies Corporation	$	(29,852	)	$	(47,507	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		149,195,028			145,787,527
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.20	)	$	(0.33	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2025 and 2024, as they had an anti-dilutive effect:


	Three Months Ended March 31,
	2025		2024
Stock options outstanding		11,968,545		13,085,872
Nonvested restricted stock units outstanding		10,598,610		10,341,199
Nonvested performance-based restricted stock units outstanding		24,995		—
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		4,311,288		2,547,757
Total		26,903,438		25,974,828